NCT07593222
Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Eligibility criteria expanded, about 14 words
- Start date changed from estimate of Sep 1, 2026 to Oct 1, 2026
- Secondary endpoints: details revised at 5 of 5 entries
- Site details revised
- Publications: details revised at 3 of 3 entries
- Notable Start date: Jul 1, 2026 to Sep 1, 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
P30 TMS-Evoked Potential (TEP) Amplitude
Timeframe: From baseline to approximately 10 minutes after cTBS administration, assessed at each of four study visits completed over a minimum of 3 to 6 weeks
Secondary (5)
Additional TEP Component Amplitudes
16-item Quick Inventory of Depressive Symptomatology (QIDS-SR16)
Patient Health Questionnaire-9 (PHQ-9)
7-item Generalized Anxiety Disorder scale (GAD-7)
24-item Behavior and Symptom Identification Scale (BASIS-24)
Arms and interventions
Sham iTBS + PlaceboSham comparator
Placebo TMS and placebo drug
iTBS + PlaceboPlacebo comparator
Active TMS and placebo drug
iTBS + D-cycloserineExperimental
Active TMS and active medication
iTBS + dextromethorphanExperimental
Active TMS and active medication
Devices: Sham iTBS, TMS
Drugs: D-cycloserine, Dextromethophan, Placebo
Sites
1 site in 1 country
- McLean HospitalBelmont, Massachusetts, United States